查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1976601

肺炎檢測​​市場：依檢測類型、技術平台、檢體類型、最終用戶和通路分類－2026-2032年全球預測

Pneumonia Testing Market by Test Type, Technology Platform, Sample Type, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺炎檢測市場價值將達到 16.8 億美元，到 2026 年將成長到 18 億美元，到 2032 年將達到 27.1 億美元，複合年成長率為 7.02%。

主要市場統計數據
基準年 2025 16.8億美元
預計年份：2026年 18億美元
預測年份 2032 27.1億美元
複合年成長率 (%) 7.02%

簡要概述臨床重點、檢查室實務和診斷技術創新如何融合，從而重新定義肺炎檢測途徑。

由於臨床需求、技術成熟以及醫療服務模式的變革，肺炎診斷領域正經歷快速的重組。臨床醫生和實驗室管理人員越來越關注能夠縮短反應時間、提高病原體特異性並實現標靶抗生素治療的診斷路徑。因此，兼具分子水平靈敏度和易用性的診斷方法變得日益重要，而傳統的基於培養的方法在複雜病例中仍然發揮著至關重要的作用，能夠提供明確的診斷和藥敏數據。

分子檢測的快速分散化、免疫檢測性能的提高以及更聰明的影像整合如何重塑肺炎的診斷和治療模式。

肺炎診斷領域正經歷著一場變革，這主要歸因於多種因素的共同作用，包括技術進步、醫療服務模式的變革以及人們對診斷速度和特異性的日益成長的期望。曾經需要中心檢查室基礎設施的分子診斷平台，如今正以分散式形式提供，幫助臨床醫生在診療過程中做出決策。同時，免疫檢測和側向層析技術的進步提升了分析能力，使其能夠在傳統實驗室之外廣泛應用於篩檢和監測。

本研究評估了近期關稅調整對加強供應鏈韌性、區域性轉移製造地以及調整診斷試劑分銷中的策略採購方法的影響。

2025年的關稅政策變化為診斷產品和耗材分銷領域的相關人員帶來了重大的營運和策略考量。進口關稅和跨境貿易條件的調整影響了採購決策，促使製造商和經銷商重新評估其供應鏈佈局、庫存緩衝和區域製造夥伴關係。在許多情況下，先前依賴少數國際供應商的企業已實現供應商多元化，以降低貿易政策波動帶來的風險。

策略性細分，詳細分析測試類型、技術平台、最終用戶工作流程、檢體模式和分銷管道的複雜性如何決定產品和市場的適用性。

關鍵的市場細分洞察凸顯了產品開發、臨床應用和分銷策略需要與不同的檢測方法和終端用戶需求相符。依檢測類型分類，市場涵蓋培養法、免疫檢測法、分子診斷法和放射影像法。在培養法中，細菌和真菌亞種的鑑定對於合理使用抗生素和複雜感染疾病的管理至關重要。免疫檢測分為抗體法和抗原法，可用於急性期診斷和血清學監測。分子檢測法又可細分為等溫擴增法和RT-PCR技術，在速度和分析靈敏度方面各有優劣。放射影像法分為電腦斷層掃描和X光檢查，分別在急性期評估和長期監測中發揮不同的作用。

從不同地區的比較觀點來看，醫療保健基礎設施、管理體制和製造能力的差異如何影響肺炎診斷方法的引入和部署。

區域趨勢揭示了需求促進因素、基礎設施能力和政策環境的差異，這些差異影響診斷策略和投資重點。在美洲，先進的檢測網路以及門診和社區醫療機構照護現場檢測的廣泛應用，催生了對快速分子檢測和免疫檢測解決方案的強勁需求，這些方案有助於合理使用抗生素和最佳化急救流程。同時，歐洲、中東和非洲的情況更為複雜，既有功能強大的三級醫療中心，也有資源匱乏的醫療機構。這種兩極化凸顯了模組化平台和擴充性成像解決方案的重要性，這些方案既能部署在不同的醫療環境中，又能滿足嚴格的監管標準。

這項對產業策略的深刻分析揭示了產品模組化、合作夥伴檢驗和通路多樣性如何定義診斷領域的競爭優勢。

產業相關人員展現出多元化的策略方針，體現了他們在創新、規模和服務交付方面的不同優先事項。領先的診斷開發公司優先考慮平台模組化，以使其能夠在照護現場、中心檢查室和參考網路中使用；而其他公司則專注於高度專業化的檢測方法，以解決病原體特異性或抗藥性檢測等特定領域的問題。儀器製造商與臨床實驗室網路之間的合作日益普遍，以此加速臨床檢驗並將新技術整合到現有工作流程中。

針對不同的臨床和分銷環境，提出加強互通性、保障區域供應鏈和商業化的實用建議。

為了將洞察轉化為營運優勢，產業領導者應專注於推廣旨在增強診斷可靠性、加速部署和提升供應鏈靈活性的各項措施。優先考慮跨平台的互通性和標準化資料格式，以實現檢測結果和影像輸出與電子健康記錄 (EHR) 和臨床決策支援工具的互通性整合。這種互通性能夠減少臨床醫生工作流程中的摩擦，並支援下游分析，從而促進品質改進和監測。

透過採用嚴格的混合調查方法，結合現場臨床訪談、技術檢驗審查和供應鏈映射，我們獲得了基於證據的、可操作的見解。

本分析的調查方法採用混合方法，以獲得可靠的三角驗證結果。主要研究包括對臨床實驗室部門主管、醫院採購負責人、放射科負責人和照護現場醫生進行結構化訪談，以了解營運重點和實際工作流程的限制。此外，還與測試開發人員和生產經理進行了技術諮詢，以明確平台功能、法規遵循途徑和生產注意事項，從而補充了這些定性見解。

綜合分析強調綜合診斷策略、供應鏈韌性以及與多樣化臨床工作流程的協調一致，從而推動患者療效的改善。

總之，肺炎診斷生態系統正朝著更一體化、靈活且更具韌性的模式發展，使技術能力與臨床需求相契合。分子診斷和免疫檢測平台正以支援分散式檢查的形式日益普及，而放射診斷技術的創新也持續提升診斷的清晰度和分診決策的準確性。同時，供應鏈和政策的發展凸顯了多元化採購和區域化生產策略的必要性，以確保關鍵耗材和平台的可靠供應。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依檢測方法分類的肺炎檢測市場

  • 培養試驗
    • 細菌培養
    • 真菌培養
  • 免疫檢測測定
    • 抗體檢測
    • 抗原檢測
  • 分子檢測
  • 放射影像
    • 電腦斷層掃描
    • X光

第9章：依技術平台分類的肺炎檢測市場

  • 數位放射線
  • 等溫擴增法
  • 橫向流動化驗
  • RT-PCR

第10章：依樣本類型分類的肺炎檢體市場

  • 血
  • 支氣管肺泡灌洗液
  • 鼻咽拭子
  • 痰

第11章 肺炎檢測市場：依最終用戶分類

  • 居家醫療
  • 醫院檢查室
    • 院內檢查室
    • 外包服務
  • 即時檢測
  • 參考檢查室

第12章：肺炎檢測市場：依通路分類

  • 離線
  • 線上

第13章 肺炎檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 肺炎檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 肺炎檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國肺炎檢測市場

第17章：中國肺炎檢測市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson and Company
  • bioMerieux SA
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • Hain Lifescience GmbH by Bruker Corporation
  • Hologic, Inc.
  • Intec Products, Inc.
  • PerkinElmer, Inc.
  • Qiagen NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-69324464D0F1

The Pneumonia Testing Market was valued at USD 1.68 billion in 2025 and is projected to grow to USD 1.80 billion in 2026, with a CAGR of 7.02%, reaching USD 2.71 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.68 billion
Estimated Year [2026] USD 1.80 billion
Forecast Year [2032] USD 2.71 billion
CAGR (%) 7.02%

A concise overview of how clinical priorities, laboratory practices, and diagnostic innovations are converging to redefine pneumonia testing pathways

The landscape of pneumonia diagnostics is undergoing a rapid reorientation driven by clinical need, technological maturation, and shifting healthcare delivery models. Clinicians and laboratory leaders are increasingly focused on diagnostic pathways that reduce time-to-result, improve pathogen specificity, and enable targeted antimicrobial stewardship. Consequently, diagnostic modalities that integrate molecular sensitivity with operational simplicity have risen in prominence, while traditional culture-based approaches continue to provide essential confirmatory and susceptibility data for complex cases.

At the same time, radiological imaging remains indispensable for disease staging and treatment decisions, particularly where structural complications are suspected. Diagnostic decision-making now frequently involves layered approaches that combine molecular testing, immunoassays, cultures, and imaging to build a comprehensive clinical picture. This hybrid diagnostic paradigm is reinforced by advances in point-of-care platforms that push testing closer to the patient, enabling rapid triage and early intervention.

In summary, the introductory context frames pneumonia testing as a convergent field where laboratory innovation, clinical imperatives, and system-level workflows intersect. Understanding these dynamics is foundational for stakeholders who aim to align product development, laboratory operations, and clinical protocols with evolving standards of care and emerging diagnostic capabilities.

How rapid decentralization of molecular testing, improved immunoassay performance, and smarter imaging integration are reshaping pneumonia diagnostics and care models

The diagnostic landscape for pneumonia is experiencing transformative shifts driven by several converging forces including technological advances, altered care delivery models, and heightened expectations for diagnostic speed and specificity. Molecular platforms that once required centralized laboratory infrastructure are increasingly available in decentralized formats, enabling clinicians to make same-encounter decisions. Meanwhile, immunoassays and lateral flow technologies have improved in analytical performance, supporting broader screening and surveillance use cases outside traditional labs.

Digital radiography and high-resolution imaging continue to benefit from software enhancements and AI-driven interpretation tools that improve lesion detection and standardize reporting. As a result, imaging is no longer purely confirmatory; it contributes actively to diagnostic algorithms when integrated with laboratory data. Another notable shift is the growing importance of sample diversity-nasopharyngeal swabs, sputum, bronchoalveolar lavage, and blood each offer complementary diagnostic yield, prompting laboratories to refine collection and processing workflows accordingly.

Taken together, these shifts are producing more adaptive diagnostic pathways that balance sensitivity, turnaround time, and operational feasibility. Health systems are recalibrating procurement and trial strategies to accommodate integrated testing solutions, while manufacturers prioritize modularity and interoperability. The net effect is a more resilient diagnostic ecosystem capable of addressing routine pneumonia cases and complex, high-acuity presentations alike.

Assessing how recent tariff adjustments have catalyzed supply chain resilience, regional manufacturing shifts, and strategic sourcing adaptations across diagnostics distribution

Tariff policy changes in 2025 have created notable operational and strategic considerations for stakeholders involved in the flow of diagnostic products and supplies. Adjustments to import duties and cross-border trade terms have influenced sourcing decisions, prompting manufacturers and distributors to reassess supply chain footprint, inventory buffers, and regional manufacturing partnerships. In many cases, organizations that previously relied on a limited set of international suppliers diversified their vendor base to mitigate exposure to trade policy volatility.

Consequently, procurement teams updated contracting strategies to incorporate contingency clauses and longer lead-time planning for critical consumables such as reagents, swabs, and cartridges. For some laboratories and device providers, these measures translated into increased emphasis on regional manufacturing and local assembly to reduce tariff impact and secure continuity of supply. At the same time, distributors and channel partners adjusted pricing tables and commercial terms to absorb and redistribute cost fluctuations without disrupting client services.

Overall, the cumulative effect of tariff adjustments in 2025 underscores the importance of supply chain resilience and strategic sourcing. Moving forward, stakeholders are expected to prioritize flexibility in manufacturing partnerships and greater transparency across distribution channels to ensure reliable access to essential diagnostic products while managing cost pressures responsibly.

Strategic segmentation analysis detailing how test type intricacies, technology platforms, end-user workflows, sample modalities, and distribution channels determine product-market fit

Key segmentation insights reveal how product development, clinical adoption, and distribution strategies must align with diverse testing modalities and end-user needs. Based on test type, the market encompasses culture methods, immunoassays, molecular diagnostics, and radiological imaging; within culture, bacterial and fungal subtypes remain critical for antimicrobial stewardship and complex infections, while immunoassay testing divides into antibody and antigen approaches that support both acute diagnosis and serological surveillance. Molecular testing is further differentiated by isothermal amplification and RT-PCR techniques, offering distinct trade-offs between speed and analytical sensitivity. Radiological imaging branches into CT scan and X-ray applications, which serve distinct roles in acuity assessment and longitudinal monitoring.

In terms of technology platform, solutions include digital radiography, isothermal amplification, lateral flow assays, and RT-PCR instruments, each bringing unique operational footprints and training requirements. End-user segmentation spans home care, hospital laboratories, point-of-care testing, and reference laboratories, with hospital laboratories further classified into in-house labs and outsourced services; these distinctions affect procurement cycles, quality control expectations, and data integration needs. Sample type considerations cover blood, bronchoalveolar lavage, nasopharyngeal swabs, and sputum, driving upstream logistics for collection, transport, and pre-analytic handling. Distribution channel dynamics involve direct sales, distributors, and online channels, which require tailored commercial models and regulatory navigation.

Collectively, these segmentation layers inform targeted product design, commercialization plans, and clinical pathways. Manufacturers and service providers that map solutions to specific segment needs-such as rapid molecular tests optimized for point-of-care settings or robust culture platforms suited to reference laboratories-will be better positioned to address heterogenous clinical workflows and procurement preferences.

Comparative regional perspectives highlighting how diverse healthcare infrastructures, regulatory regimes, and manufacturing capabilities influence pneumonia diagnostics adoption and deployment

Regional dynamics reveal differentiated demand drivers, infrastructure capacities, and policy environments that shape diagnostic strategy and investment priorities. The Americas region combines advanced laboratory networks with significant point-of-care adoption in outpatient and community settings, creating strong demand for rapid molecular and immunoassay solutions that support antimicrobial stewardship and emergency care workflows. In contrast, Europe, Middle East & Africa presents a more heterogeneous landscape where high-capacity tertiary centers coexist with resource-constrained settings; this dichotomy elevates the importance of modular platforms and scalable imaging solutions that can be deployed across diverse care settings while meeting stringent regulatory standards.

Asia-Pacific exhibits high innovation uptake and rapid diffusion of digital health technologies, driven by large patient volumes, expanding private healthcare sectors, and growing regional manufacturing capabilities. These factors encourage the development of cost-effective assays and locally optimized supply chains. Across all regions, however, common themes emerge: a focus on reducing diagnostic turnaround time, improving interoperability of laboratory and radiology data, and strengthening supply chain resilience through regional partnerships. Policy and reimbursement frameworks continue to be pivotal in determining adoption speed and investment levels, and stakeholders that tailor strategies to regional regulatory and operational realities will achieve more sustainable implementation and scale.

Understanding these regional nuances is essential for aligning commercial strategies, clinical validation efforts, and manufacturing footprints to ensure durable adoption and reliable service delivery across global markets.

Insightful analysis of industry strategies showing how product modularity, partner validation, and channel diversity are defining competitive advantage in diagnostics

Industry participants demonstrate a spectrum of strategic approaches that reflect priorities across innovation, scale, and service delivery. Leading diagnostic developers prioritize platform modularity to enable use across point-of-care settings, centralized laboratories, and reference networks, while others focus on highly specialized assays that address pathogen-specific or resistance-detection niches. Partnerships between device firms and clinical laboratory networks have become more common as a means to accelerate clinical validation and to embed new technologies within established workflows.

Commercial strategies also vary by channel orientation: some companies double down on direct sales and laboratory service models to maintain tight control over quality and customer engagement, whereas others leverage distributor networks and digital marketplaces to extend reach and streamline procurement for decentralized customers. In parallel, several firms are exploring companion digital tools and analytics services to enhance diagnostic interpretation, monitor performance in real time, and offer value-added support to clinicians and lab managers.

Ultimately, competitive differentiation is being shaped by the ability to integrate diagnostics into clinical decision pathways, ensure robust supply chain continuity, and deliver scalable customer support. Organizations that balance technological excellence with pragmatic deployment models and thoughtful channel strategies are best positioned to capture sustainable adoption across care settings.

Actionable recommendations for leaders to enhance interoperability, secure regional supply chains, and tailor commercialization for diverse clinical and distribution environments

To translate insights into operational advantage, industry leaders should pursue targeted initiatives that strengthen diagnostic reliability, speed adoption, and enhance supply chain agility. First, prioritize platform interoperability and standardized data formats to ensure that test results and imaging outputs can be integrated seamlessly into electronic health records and clinical decision support tools. This interoperability reduces friction in clinician workflows and supports downstream analytics for quality improvement and surveillance.

Second, invest in regional manufacturing partnerships and multi-sourcing strategies to minimize exposure to trade disruptions and tariff-related cost shifts. Establishing near-shore assembly or contracted production arrangements can shorten lead times and improve responsiveness to demand fluctuations. Third, tailor commercialization models to end-user contexts: emphasize ease-of-use and rapid turnaround for point-of-care deployments, robustness and throughput for hospital and reference laboratories, and home-use-friendly interfaces for remote care settings. Fourth, strengthen clinical evidence generation by designing validation studies that reflect real-world sample diversity, including blood, bronchoalveolar lavage, nasopharyngeal swabs, and sputum, to support broader clinical acceptance.

Finally, develop flexible distribution strategies that combine direct sales for high-touch customers, distributor partnerships for geographic reach, and online channels for convenience. Executing these recommendations will help organizations accelerate adoption, mitigate operational risk, and deliver measurable clinical and economic value to healthcare partners.

A rigorous mixed-methods research approach combining frontline clinical interviews, technical validation review, and supply chain mapping to ensure defensible and actionable findings

The research methodology underpinning this analysis employed a mixed-methods approach to ensure robust, triangulated insights. Primary research included structured interviews with clinical laboratory directors, hospital procurement officers, radiology leaders, and point-of-care clinicians to capture operational priorities and real-world workflow constraints. These qualitative inputs were complemented by technical consultations with assay developers and manufacturing leaders to elucidate platform capabilities, regulatory pathways, and production considerations.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and technical performance summaries from manufacturers, with particular attention to analytical sensitivity, specificity, and operational requirements of different technologies. The analysis also incorporated supply chain mapping exercises to identify key nodes susceptible to disruption and to assess the implications of tariff changes on procurement and distribution models.

Data validation was performed through cross-referencing stakeholder interviews with published clinical validation studies and regulatory filings to ensure consistency. Wherever feasible, findings were stress-tested against alternative scenarios to evaluate resilience under varying operational constraints. The resulting methodology balances empirical evidence with practitioner insight to yield a pragmatic and defensible assessment of the pneumonia diagnostics landscape.

Concluding synthesis emphasizing integrated diagnostic strategies, supply chain resilience, and alignment with diverse clinical workflows to improve patient outcomes

In conclusion, the pneumonia diagnostics ecosystem is evolving toward more integrated, flexible, and resilient models that align technological capability with clinical need. Molecular and immunoassay platforms are increasingly available in formats that support decentralized testing, while radiological innovations continue to enhance diagnostic clarity and triage decisions. At the same time, supply chain and policy developments underscore the need for diversified sourcing and regional manufacturing strategies to sustain reliable access to critical consumables and platforms.

For stakeholders across the value chain, the imperative is to align product design, evidence generation, and commercial models with the nuanced requirements of different user segments. Whether serving point-of-care clinicians, hospital laboratories, reference centers, or home-based care, solutions that prioritize interoperability, ease of use, and validated performance across diverse sample types will achieve more durable clinical adoption. By adopting the strategic and operational recommendations outlined earlier, organizations can better navigate trade policy dynamics, accelerate deployment of effective diagnostics, and ultimately contribute to improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Pneumonia Testing Market, by Test Type

  • 8.1. Culture
    • 8.1.1. Bacterial Culture
    • 8.1.2. Fungal Culture
  • 8.2. Immunoassay Test
    • 8.2.1. Antibody Test
    • 8.2.2. Antigen Test
  • 8.3. Molecular Test
  • 8.4. Radiological Imaging
    • 8.4.1. CT Scan
    • 8.4.2. X Ray

9. Pneumonia Testing Market, by Technology Platform

  • 9.1. Digital Radiography
  • 9.2. Isothermal Amplification
  • 9.3. Lateral Flow Assay
  • 9.4. RT PCR

10. Pneumonia Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Bronchoalveolar Lavage
  • 10.3. Nasopharyngeal Swab
  • 10.4. Sputum

11. Pneumonia Testing Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital Laboratory
    • 11.2.1. In House Lab
    • 11.2.2. Outsourced Services
  • 11.3. Point Of Care Testing
  • 11.4. Reference Laboratory

12. Pneumonia Testing Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Pneumonia Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Pneumonia Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Pneumonia Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Pneumonia Testing Market

17. China Pneumonia Testing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Becton Dickinson and Company
  • 18.7. bioMerieux SA
  • 18.8. Danaher Corporation
  • 18.9. Eurofins Scientific SE
  • 18.10. F. Hoffmann-La Roche Ltd
  • 18.11. Hain Lifescience GmbH by Bruker Corporation
  • 18.12. Hologic, Inc.
  • 18.13. Intec Products, Inc.
  • 18.14. PerkinElmer, Inc.
  • 18.15. Qiagen N.V.
  • 18.16. Siemens Healthineers AG
  • 18.17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PNEUMONIA TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PNEUMONIA TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BACTERIAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY FUNGAL CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY CT SCAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DIGITAL RADIOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY RT PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY BRONCHOALVEOLAR LAVAGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY IN HOUSE LAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OUTSOURCED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. GCC PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. GCC PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. GCC PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 185. GCC PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 186. GCC PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 187. GCC PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GCC PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. G7 PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. G7 PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. G7 PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 215. G7 PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 216. G7 PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 217. G7 PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. G7 PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 220. G7 PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. NATO PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. NATO PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NATO PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 225. NATO PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 226. NATO PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 227. NATO PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. NATO PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 230. NATO PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL PNEUMONIA TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA PNEUMONIA TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA PNEUMONIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA PNEUMONIA TESTING MARKET SIZE, BY CULTURE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA PNEUMONIA TESTING MARKET SIZE, BY IMMUNOASSAY TEST, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA PNEUMONIA TESTING MARKET SIZE, BY RADIOLOGICAL IMAGING, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA PNEUMONIA TESTING MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA PNEUMONIA TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA PNEUMONIA TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA PNEUMONIA TESTING MARKET SIZE, BY HOSPITAL LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA PNEUMONIA TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)